Live
Endpoints NewsFDA clears Gilead's hepatitis D drug, four years after prior rejectionClinical OMICsFungal Adjuvant Mannadjuvant Extends mRNA COVID-19 Vaccine ProtectionsEndpoints NewsGOP lawmaker asks Trump administration to curb China biotech dealsClinical OMICsHow Colorectal Tumors Escape KRAS Inhibitors IdentifiedClinical OMICsFDA Approves Datroway as First-Line Therapy for Triple-Negative Breast CancerBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-May 21, 2026Endpoints NewsAstraZeneca wins EU backing for breast cancer drug, splitting with FDA panelEndpoints NewsHow Utah’s AI prescribing experiment is going so farBioWorldIn the clinic for May 22, 2026BioWorldRegulatory actions for May 22, 2026BioWorldHoliday notice
FierceBiotech Apr 7, 2026

Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study

Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study

Original
Body unavailable. Use the original source.